RELIEF THERAPEUTICS : Condensed consolidated interim financial statements for the half-year ended 30 June 2019

Geneva, Switzerland, 27 September 2019

RELIEF THERAPEUTICS Holding AG ('Relief', the 'Company') published yesterday its consolidated financial results for the half-year ended 30 June 2019.

For the half-year ended 30 June 2019, the Company generated a net loss of approximately CHF 556 thousand and an EBITDA of negative CHF 532 thousand. By comparison, for the half-year ended 30 June 2018, the Company generated a loss of CHF 365 thousand and an EBITDA of negative CHF 420 thousand.

Raghuram Selvaraju, Chairman of the Board of Directors, comments: 'The half-year financial statements published yesterday reflect the efforts of the Company Management and Board of Directors to maintain its expenses at their minimum while exploring all the possible ways to ensure the future development of Relief and its projects. With the progressive implementation of our new strategy since early 2017, and the continuous support of our main investor Gem Global Yield Fund LLC SCS, we are committed to continue to drive Relief further along this constructive path.'

The 2019 interim financial statements is available here.

About Relief Therapeutics Holding AG

RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (to enter Phase III) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (to enter Phase II). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, and has been the subject of multiple clinical trials. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Geneva, Switzerland.

For further information, please visit the Relief website at www.relieftherapeutics.com or contact investor relations at:

RELIEF THERAPEUTICS Holding AG

Investor Relations

Tel: [phone]

[e-mail]

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning Relief Therapeutics Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Relief Therapeutics Holding AG is providing this communication as of this date and does not undertake to update any forward looking statements contained herein as a result of new information, future events or otherwise